Zacks: Akari Therapeutics PLC (AKTX) Given Consensus Rating of “Buy” by Analysts

Akari Therapeutics PLC (NASDAQ:AKTX) has been given a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.

Brokers have set a 1-year consensus price target of $2.50 for the company and are predicting that the company will post ($1.00) EPS for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics an industry rank of 161 out of 265 based on the ratings given to related companies.

AKTX has been the subject of several research analyst reports. Zacks Investment Research upgraded Akari Therapeutics from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective for the company in a report on Wednesday, September 20th. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. William Blair upgraded Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Canaccord Genuity reiterated a “buy” rating and issued a $15.00 price objective on shares of Akari Therapeutics in a report on Friday, September 22nd. Finally, Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics in a research note on Sunday, September 17th.

An institutional investor recently raised its position in Akari Therapeutics stock. Hikari Power Ltd boosted its stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,334 shares of the biopharmaceutical company’s stock after buying an additional 91,322 shares during the period. Hikari Power Ltd owned approximately 1.28% of Akari Therapeutics worth $929,000 at the end of the most recent reporting period. Institutional investors own 20.95% of the company’s stock.

Akari Therapeutics (NASDAQ:AKTX) traded down $0.11 during midday trading on Friday, reaching $3.95. The company’s stock had a trading volume of 388,142 shares, compared to its average volume of 326,619. Akari Therapeutics has a 1-year low of $3.18 and a 1-year high of $22.20. The stock has a market cap of $60.26, a PE ratio of -1.47 and a beta of -8.64.

WARNING: “Zacks: Akari Therapeutics PLC (AKTX) Given Consensus Rating of “Buy” by Analysts” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/13/zacks-akari-therapeutics-plc-aktx-given-consensus-rating-of-buy-by-analysts.html.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply